Immunotargeting and Radiobiology in Oncology : A. Pèlegrin


Latorzeff I, Bourgier C, Pinel B, Hennequin C, Jimenez G, Chapet O, Zasadny X [Treatment of primary disease (breast, non-small cell lung and prostate cancers) with irradiation in case of de novo metastatic cancer]. Cancer Radiother. Sep 06, 2019. doi:10.1016/j.canrad.2019.08.004

Bourgier C, Latorzeff I, Fenoglietto P, Boisselier P, Charissoux M, Llacer C, Lemanski C, Riou O, Farcy-Jacquet M-P, Azria D [Treatment of oligometastatic or oligoprogression cancer]. Cancer Radiother. Sep 05, 2019. doi:10.1016/j.canrad.2019.07.143

Riou O, Bourgier C, Brengues M, Bonnefoi N, Michaud H-A, Castan F, Gourgou S, Draghici R, Farcy-Jacquet M-P, Bons F, Fenoglietto P, Ozsahin M, Azria D [Predictive assays for responses of tumors and normal tissues in radiation oncology]. Cancer Radiother. Aug 23, 2019. doi:10.1016/j.canrad.2019.07.152

Riou O, Valdenaire S, Debuire P, Fenoglietto P, Debrigode C, Mazard T, Assenat É, Azria D [Liver stereotactic body radiotherapy: Clinical features and technical consequences, results. Which treatment machine in which situation?]. Cancer Radiother. Aug 20, 2019. doi:10.1016/j.canrad.2019.07.159

Bourgier C, Lemanski C, Draghici R, Castan F, Fenoglietto P, Bons F, Farcy-Jacquet M-P, Brengues M, Gourgou S, Ozsahin M, Azria D [Individual modification of the dose, volume and fractionation of breast radiotherapy]. Cancer Radiother. Aug 01, 2019. doi:10.1016/j.canrad.2019.06.004

Prunaretty J, Boisselier P, Riou O, Simeon S, Bedos L, Azria D, Fenoglietto P Tracking, gating, free-breathing, which technique to use for lung stereotactic treatments? A dosimetric comparison. Rep Pract Oncol Radiother. 2019;24(1):97-104. doi:10.1016/j.rpor.2018.11.003

Montero-Luis A, Aristei C, Meattini I, Arenas M, Boersma L, Bourgier C, Coles C, Cutuli B, Falcinelli L, Kaidar-Person O, Leonardi M, Offersen B, Marazzi F, Rivera S, Tagliaferri L, Tombolini V, Vidali C, Valentini V, Poortmans P The Assisi Think Tank Meeting Survey of post-mastectomy radiation therapy in ductal carcinoma in situ: Suggestions for routine practice. Crit. Rev. Oncol. Hematol.. 2019;138. doi:10.1016/j.critrevonc.2019.04.016

Amestoy F, Roubaud G, Antoine M, Fonteyne V, Baumann B, Christodouleas J, Azria D, Zilli T, Hennequin C, Xylinas E, Sargos P Review of hypo-fractionated radiotherapy for localized muscle invasive bladder cancer. Crit. Rev. Oncol. Hematol.. 2019;142. doi:10.1016/j.critrevonc.2019.06.010

Seibold P, Webb A, Aguado-Barrera M, Azria D, Brengues M, Briers E, Bultijnck R, Calvo-Crespo P, Carballo A, Choudhury A, Cicchetti A, Claßen J, Delmastro E, Dunning A, Elliott R, Farcy-Jacquet M-P, Gabriele P, Garibaldi E, Gómez-Caamaño A, Gutiérrez-Enríquez S, Higginson D, Johnson K, Lobato-Busto R, Mollà M, Müller A, Payne D, Peleteiro P, Post G, Rancati T, Rattay T, Reyes V, Rosenstein B, De Ruysscher D, De Santis M, Schäfer J, Schnabel T, Sperk E, Symonds R, Stobart H, Taboada-Valladares B, Talbot C, Valdagni R, Vega A, Veldeman L, Ward T, Weißenberger C, West C, Chang-Claude J REQUITE: A prospective multicentre cohort study of patients undergoing radiotherapy for breast, lung or prostate cancer. Radiother Oncol. 2019;138. doi:10.1016/j.radonc.2019.04.034

Lacombe J, Brengues M, Mangé A, Bourgier C, Gourgou S, Pèlegrin A, Ozsahin M, Solassol J, Azria D Quantitative proteomic analysis reveals AK2 as potential biomarker for late normal tissue radiotoxicity. Radiat Oncol. 2019;14(1):142. doi:10.1186/s13014-019-1351-8

Auperin A, Rivera S, Boisselier P, Lang P, Lassau N, Taourel P, Azria D, Bourhis J, Deutsch E, Vozenin M-C Pravastatin Reverses Established Radiation-Induced Cutaneous and Subcutaneous Fibrosis in Patients With Head and Neck Cancer: Results of the Biology-Driven Phase 2 Clinical Trial Pravacur. Int. J. Radiat. Oncol. Biol. Phys.. 2019;104(2):365-373. doi:10.1016/j.ijrobp.2019.02.024

Talbot C, Veldwijk M, Azria D, Batini C, Bierbaum M, Brengues M, Chang-Claude J, Johnson K, Keller A, Smith S, Sperk E, Symonds R, Wenz F, West C, Herskind C Multi-centre technical evaluation of the radiation-induced lymphocyte apoptosis assay as a predictive test for radiotherapy toxicity. Clin Transl Radiat Oncol. 2019;18. doi:10.1016/j.ctro.2019.06.001

Le Clorennec C, Lazrek Y, Dubreuil O, Sampaio C, Larbouret C, Lanotte R, Poul M-A, Barret J-M, Prost J-F, Pèlegrin A, Chardès T ITCH-dependent proteasomal degradation of c-FLIP induced by the anti-HER3 antibody 9F7-F11 promotes DR5/caspase 8-mediated apoptosis of tumor cells. Cell Commun. Signal. 2019;17(1):106. doi:10.1186/s12964-019-0413-8

Boige V, Mollevi C, Gourgou S, Azria D, Seitz J-F, Vincent M, Bigot L, Juzyna B, Miran I, Gerard J-P, Laurent-Puig P Impact of single-nucleotide polymorphisms in DNA repair pathway genes on response to chemoradiotherapy in rectal cancer patients: Results from ACCORD-12/PRODIGE-2 phase III trial. Int. J. Cancer. May 20, 2019. doi:10.1002/ijc.32417

Kaidar-Person O, Vrou Offersen B, Hol S, Arenas M, Aristei C, Joao Cardoso M, Chua B, Coles C, Engberg Damsgaard T, Gabrys D, Jagsi R, Jimenez R, Kirby A, Kirkove C, Kirova Y, Kouloulias V, Marinko T, Meattini I, Mjaaland I, Nader Marta G, Witt Nystrom P, Senkus E, Skyttä T, Tvedskov T, Verhoeven K, Poortmans P ESTRO ACROP consensus guideline for target volume delineation in the setting of postmastectomy radiation therapy after implant-based immediate reconstruction for early stage breast cancer. Radiother Oncol. 2019;137. doi:10.1016/j.radonc.2019.04.010

Borg C, Mantion G, Boudghène F, Mornex F, Ghiringhelli F, Adenis A, Azria D, Balosso J, Ben Abdelghani M, Bachet J, Vendrely V, François Y, Conroy T, Rio E, Roullet B, Spaëth D, Quero L, Lakkis Z, Coudert M, Ionescu-Goga M, Tanang A, André T Efficacy and Safety of Two Neoadjuvant Strategies With Bevacizumab in MRI-Defined Locally Advanced T3 Resectable Rectal Cancer: Final Results of a Randomized, Noncomparative Phase 2 INOVA Study. Clin Colorectal Cancer. May 03, 2019. doi:10.1016/j.clcc.2019.04.006

Budna-Tukan J, ?wierczewska M, Mazel M, Cie?likowski W, Ida A, Jankowiak A, Antczak A, Nowicki M, Pantel K, Azria D, Zabel M, Alix-Panabières C Analysis of Circulating Tumor Cells in Patients with Non-Metastatic High-Risk Prostate Cancer before and after Radiotherapy Using Three Different Enumeration Assays. Cancers (Basel). 2019;11(6). doi:10.3390/cancers11060802

Neiveyans M, Melhem R, Arnoult C, Bourquard T, Jarlier M, Busson M, Laroche A, Cerutti M, Pugnières M, Ternant D, Gaborit N, Chardès T, Poupon A, Gouilleux-Gruart V, Poul M-A A recycling anti-transferrin receptor-1 monoclonal antibody as an efficient therapy for erythroleukemia through target up-regulation and antibody-dependent cytotoxic effector functions. MAbs. Jan 03, 2019. doi:10.1080/19420862.2018.1564510

Bourgier C, Lemanski C, Fenoglietto P, Azria D [The major debate: Micrometastases and breast cancer - To be for nodal irradiation]. Cancer Radiother. Aug 22, 2018. doi:10.1016/j.canrad.2018.07.129

Kammerer E, Fenoglietto P, Bourgier C [Modalities and advantages of image guided radiation therapy of breast cancer in adjuvant setting]. Cancer Radiother. Aug 22, 2018. doi:10.1016/j.canrad.2018.07.126

Rozet F, Hennequin C, Beauval J-B, Beuzeboc P, Cormier L, Fromont-Hankard G, Mongiat-Artus P, Ploussard G, Mathieu R, Brureau L, Ouzzane A, Azria D, Brenot-Rossi I, Cancel-Tassin G, Cussenot O, Rebillard X, Lebret T, Renard Penna R, Méjean A [French ccAFU guidelines - Update 2018-2020: Prostate cancer]. Prog. Urol.. 2018;28 Suppl 1. doi:10.1016/j.purol.2019.01.007

Aristei C, Kaidar-Person O, Tagliaferri L, Arenas M, Coles C, Offersen B, Frezza G, Leonardi M, Valentini V, Bourgier C, Poortmans P The Assisi Think Tank Meeting and Survey of post MAstectomy Radiation Therapy after breast reconstruction: The ATTM-SMART report. Eur J Surg Oncol. 2018;44(4):436-443. doi:10.1016/j.ejso.2018.01.010

Ogier C, Colombo P-E, Bousquet C, Canterel-Thouennon L, Sicard P, Garambois V, Thomas G, Gaborit N, Jarlier M, Pirot N, Pugnière M, Vie N, Gongora C, Martineau P, Robert B, Pèlegrin A, Chardès T, Larbouret C Targeting the NRG1/HER3 pathway in tumor cells and cancer-associated fibroblasts with an anti-neuregulin 1 antibody inhibits tumor growth in pre-clinical models of pancreatic cancer. Cancer Lett.. 2018;432. doi:10.1016/j.canlet.2018.06.023

Ogier C, Colombo P-E, Bousquet C, Canterel-Thouennon L, Sicard P, Garambois V, Thomas G, Gaborit N, Jarlier M, Pirot N, Pugnière M, Vie N, Gongora C, Martineau P, Robert B, Pèlegrin A, Chardès T, Larbouret C Targeting the NRG1/HER3 pathway in tumor cells and cancer-associated fibroblasts with an anti-neuregulin 1 antibody inhibits tumor growth in pre-clinical models of pancreatic cancer. Cancer Lett.. 2018;432. doi:10.1016/j.canlet.2018.06.023

Boogerd L, Hoogstins C, Schaap D, Kusters M, Handgraaf H, van der Valk M, Hilling D, Holman F, Peeters K, Mieog J, van de Velde C, Farina-Sarasqueta A, van Lijnschoten I, Framery B, Pèlegrin A, Gutowski M, Nienhuijs S, de Hingh I, Nieuwenhuijzen G, Rutten H, Burggraaf J, Vahrmeijer A Safety and effectiveness of SGM-101, a fluorescent antibody targeting carcinoembryonic antigen, for intraoperative detection of colorectal cancer: a dose-escalation pilot study. Lancet Gastroenterol Hepatol. 2018;3(3):181-191. doi:10.1016/S2468-1253(17)30395-3

© Institut de Recherche en Cancérologie de Montpellier - 2011 - Tous droits réservés - Mentions légales - Connexion - Conception : ID Alizés